412 related articles for article (PubMed ID: 16618724)
21. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer.
Kurakawa E; Shimamoto T; Utsumi K; Hirano T; Kato H; Ohyashiki K
Int J Oncol; 2001 Aug; 19(2):277-81. PubMed ID: 11445839
[TBL] [Abstract][Full Text] [Related]
23. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications.
González-Quevedo R; García-Aranda C; Morán A; De Juan C; Sánchez-Pernaute A; Torres A; Díaz-Rubio E; Balibrea JL; Benito M; Iniesta P
Int J Oncol; 2004 Feb; 24(2):349-55. PubMed ID: 14719111
[TBL] [Abstract][Full Text] [Related]
24. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
[TBL] [Abstract][Full Text] [Related]
25. Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood.
Tan S; Sun C; Wei X; Li Y; Wu Y; Yan Z; Feng F; Wang J; Wu Y
Exp Lung Res; 2013; 39(4-5):182-90. PubMed ID: 23614702
[TBL] [Abstract][Full Text] [Related]
26. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
27. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.
Gu J; Berman D; Lu C; Wistuba II; Roth JA; Frazier M; Spitz MR; Wu X
Clin Cancer Res; 2006 Dec; 12(24):7329-38. PubMed ID: 17189404
[TBL] [Abstract][Full Text] [Related]
28. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
29. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma.
Tomizawa Y; Nakajima T; Kohno T; Saito R; Yamaguchi N; Yokota J
Cancer Res; 1998 Dec; 58(23):5478-83. PubMed ID: 9850082
[TBL] [Abstract][Full Text] [Related]
31. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.
Kim DH; Kim JS; Park JH; Lee SK; Ji YI; Kwon YM; Shim YM; Han J; Park J
Cancer Res; 2003 Oct; 63(19):6206-11. PubMed ID: 14559805
[TBL] [Abstract][Full Text] [Related]
32. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
[TBL] [Abstract][Full Text] [Related]
33. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers.
Tseng JE; Kemp BL; Khuri FR; Kurie JM; Lee JS; Zhou X; Liu D; Hong WK; Mao L
Cancer Res; 1999 Oct; 59(19):4798-803. PubMed ID: 10519387
[TBL] [Abstract][Full Text] [Related]
34. Promoter methylation of retinoic acid receptor beta 2 and the development of second primary lung cancers in non-small-cell lung cancer.
Kim JS; Lee H; Kim H; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Sep; 22(17):3443-50. PubMed ID: 15277540
[TBL] [Abstract][Full Text] [Related]
35. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma.
Takada S; Morita K; Hayashi K; Matsushima T; Sawamura M; Murakami H; Nojima Y
Eur J Haematol; 2005 Dec; 75(6):505-10. PubMed ID: 16313263
[TBL] [Abstract][Full Text] [Related]
36. Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer.
Sirera R; Gil M; Blasco A; Cabrera A; Safont MJ; Iranzo V; Cayuela D; Rosell R; Camps C
Lung Cancer; 2008 Jul; 61(1):104-8. PubMed ID: 18243403
[TBL] [Abstract][Full Text] [Related]
37. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
38. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
40. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
